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ORIGINAL ARTICLE
Outcome after failure of allogeneic hematopoietic stem cell
transplantation in children with acute leukemia: a study by
the société Francophone de greffe de moelle et de thérapie
cellulaire (SFGM-TC)
C Roux1,2, K Tifratene3, G Socié4, C Galambrun5, Y Bertrand6, F Rialland7, C Jubert8, C Pochon9, C Paillard10, A Sirvent11, B Nelken12,
JP Vannier13, C Freycon14, Y Beguin15, N Raus16, I Yakoub-Agha17, M Mohty18, J-H Dalle19, G Michel5, C Pradier3,
R Peffault de Latour4 and P-S Rohrlich2,20
Allogeneic hematopoietic stem cell transplantation (SCT) contributes to improved outcome in childhood acute leukemia (AL).
However, therapeutic options are poorly deﬁned in the case of post-transplantation relapse. We aimed to compare treatment
strategies in 334 consecutive children with acute leukemia relapse or progression after SCT in a recent 10-year period. Data could
be analyzed in 288 patients (157 ALL, 123 AML and 8 biphenotypic AL) with a median age of 8.16 years at transplantation. The
median delay from ﬁrst SCT to relapse or progression was 182 days. The treatment consisted of chemotherapy alone (n= 108),
chemotherapy followed by second SCT (n= 70), supportive/palliative care (n= 67), combination of chemotherapy and donor
lymphocyte infusion (DLI; n= 30), or isolated reinfusion of donor lymphocytes (DLI; n= 13). The median OS duration after
relapse was 164 days and differed according to therapy: DLI after chemotherapy = 385 days, second allograft = 391 days,
chemotherapy = 174 days, DLI alone = 140 days, palliative care = 43 days. A second SCT or a combination of chemotherapy and DLI
yielded similar outcome (hazard ratio (HR) = 0.85, P= 0.53) unlike chemotherapy alone (HR = 1.43 P= 0.04), palliative care (HR= 4.24,
Po0.0001) or isolated DLI (HR= 1,94, Po0.04). Despite limitations in this retrospective setting, strategies including
immunointervention appear superior to other approaches, mostly in AML.
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INTRODUCTION
Hematopoietic stem cell transplantation (SCT) has contributed to
improved outcome for pediatric patients with acute leukemia (AL).
However, post-transplantation relapse is still associated with a
dismal prognosis and its optimal treatment remains unclear.
Therapeutic treatments for patients who relapse after ﬁrst
SCT are limited. Treatment options include supportive care,
chemotherapy,1,2 second SCT using the same or an alternative
donor3–8 and more recently donor lymphocyte infusion (DLI).9–13
So far, no standard approach to this difﬁcult clinical problem has
been established. Therapeutic strategies may vary according to
the delay between transplant and relapse, as well as centers and
child’s speciﬁc requirements.
We aimed to compare survival according to different treatment
strategies, in case of relapse or progression post allogeneic SCT in
children with acute leukemia in a recent 10-year period.
MATERIALS AND METHODS
Data collection
We analyzed all consecutive children (o18 years), who received a ﬁrst
allogeneic SCT for ALL or AML from January 2000 to December 2009 and
experienced a relapse or progression thereafter. Clinical data were
prospectively collected using ProMISe (Project Manager Internet Server),
an internet-based data registry system shared by the 33 centers of the
SFGM-TC (French Society of Bone Marrow Transplantation and Cell
Therapies) who participated in this study.
The study was designed by the SFGM-TC. The study was approved by
the ethics committee at each participating institution and was conducted
in accordance with the consent of patients.
The primary end point was overall survival (OS) after diagnosis of relapse
or progression post ﬁrst SCT whatever the treatment post relapse was.
Failure was deﬁned as hematological relapse (deﬁned by recurrence of
blasts in peripheral blood, or inﬁltration of bone marrow by more than
5% blasts) or progression of the initial leukemia. Secondary tumors were
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excluded. Secondary end points included OS after (i) second SCT,
(ii) chemotherapy alone, (iii) DLI, (iv) chemotherapy followed by DLI or
(v) supportive and palliative care. We also assessed the prognostic risk
factors for survival after failure post SCT.
Eligibility criteria
Inclusion was based on the following criteria: age o18 years at ﬁrst
allogeneic transplant, diagnosis of acute leukemia (lymphoid acute
leukemia or myeloid acute leukemia), relapse or progression after ﬁrst
SCT, available follow-up data, ﬁrst allogeneic SCT for ALL or AML from
January 2000 to December 2009.
Statistical analysis
Descriptive analyses were created for all study variables using means, SDs,
medians, ranges and percentages where appropriate. Quantitative
variable were categorized if needed using median, terciles or quartiles.
Kaplan–Meier analysis was performed to report survival times and
associations between progression and variables were tested with log-rank
test.14 Overall survival was deﬁned as the time from the date of relapse
after ﬁrst transplantation or non-remission assessment date until the date
of death.
We used a Cox proportional-hazards regression model to examine
simultaneously the effects of multiple covariates on survival. We ﬁrst
performed univariate Cox analyses and covariates that achieved a
signiﬁcance level of P⩽ 0.2 were taken to the multivariate model. Tests
for interaction between pairs of variables in the ﬁnal models were also
performed. The effect of each variable in these models was assessed with
the use of the Wald test and described by the hazard ratio (HR), with 95%
conﬁdence interval. Subjects with missing additional therapy after ﬁrst
relapse were excluded from the Cox models. The ﬁnal models were
developed by introducing all variables of interest in a stepwise backward
multivariate analysis. We checked the adequacy of all models using
graphical techniques. As the proportion of missing data for therapy
variable was 13.8%, secondary analysis was performed using multiple
imputation. Missing therapy data were imputed randomly 10 times from
scores of similar patients with complete data, and the method of multiple
imputation15 was applied to the 10 full data sets so created. The outcome
(overall survival) was included among the predictors of these missing data.
We addressed the question of the relation between time to relapse and
post-relapse treatment choice in two ways; ﬁrst:we entered time to relapse
as a covariate in the Cox models explaining overall survival of the
population; second:we systematically tested for second-order interaction
between time to relapse and post-relapse treatment. The P-values for
interaction tests were not signiﬁcant and around 0.90. So we did not ﬁnd
any interaction and did not include this interaction term in our models.
Statistical analyses were performed with PASW software version 18.0
(SPSS, Chicago, IL, USA).
RESULTS
Between January 2000 and December 2009, 1307 children received
a ﬁrst SCT for acute leukemia. (ALL n=761, AML n=501,
biphenotypic AL n=45). Of whom, 334 children (25.5%) relapsed
or progressed thereafter. In 46 of them, the post failure data were
not available and 288 patients were thus included in the analysis.
The median overall survival of the 46 excluded children was
2.6 months versus 5.3 months for the 288 analyzed patients. We did
not observe any signiﬁcant difference in the median time from
transplantation to relapse or progression between included and
excluded population (182 days and 180 days, respectively). Analyzed
patients had a better median follow-up (160 days and 80 days for
excluded children). ALL was the most frequent type of leukemia
(n=157) (B-cell phenotype, n=127; T-cell phenotype, n=30),
followed by AML (n=123) and biphenotypic AL (n=8; Table 1). At
transplantation, 236 (82%) patients were in CR (CR1, n=122, CR2
n=98, CR3 n=16), whereas 52 (18%) had a cytologically detectable
disease. Donors were matched related siblings (n=103, 36%),
mismatched unrelated (n=70, 24%), matched unrelated (n=51,
18%), unrelated without precision (n=46, 16%), mismatched related
(n=11, 4%) or syngeneic (n=5, 2%). Stem cell source was bone
marrow (n=184, 65%), umbilical cord blood (n=67, 23%) or
peripheral stem cells (n=34, 12%) . Median time from diagnosis
to ﬁrst SCT was 245 days. Ninety-one percent (n=263) of the
children received a myeloablative regimen and 9% (n=25) received
reduced intensity conditioning regimen. TBI was performed in 159
children (55%). Acute GvHD after ﬁrst SCT occurred in 161 patients
(56%; grade I n=62 (38%), grade II to IV n=99 (62%)). The median
time from ﬁrst SCT to relapse/progression was 182 days. The
treatments for relapse after ﬁrst SCT consisted in reinduction
chemotherapy alone aiming at obtaining a CR (n=108, 37%),
chemotherapy followed by second SCT (n=70, 24%), best
supportive care including palliative chemotherapy (n=67, 23%),
combination of chemotherapy and DLI (n=30 10%), or isolated DLI
(n=13, 6%; Table 2). Analysis of the type of reinduction
chemotherapy was hampered by the too large number of different
regimens.
At the time of analysis in December 2014, 12% of children were
alive with a median follow-up of 1315 days (ranges 58–4182). The
median OS duration after relapse was 164 days among the 288
patients (Figure 1). ALL was associated with a better outcome as
compared with AML (P= 0.006; Figure 2).
Prognostic factors
The following variables impacted the outcome: age at ﬁrst transplant
between 5 and 9 (HR=0.64, Po0.002) and GvHD occurrence afterTable 1. Characteristics of the 288 patients included in the
retrospective study
Characteristics Number of patients and percentage





B ALL 127 (43.9%)









⩾ 355 73 (25.3%)

















Chemotherapy 100 27.9 174 118.7 229.4
Second SCT 70 51.0 391 264.3 517.7
Palliative care 73 4.5 43 32.7 53.3
Chemotherapy
and DLI
30 53.3 385 293.7 476.2
DLI 13 15.4 140 9.6 270.3
Global 288 30.2 164 127.7 200.2
Abbreviations: CI= conﬁdence interval; DLI=donor lymphocyte infusion;
SCT= stem cell transplantation. Log-rank test: Po10− 5.
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the ﬁrst transplant (HR=0.60 Po0.002) were associated with a
better outcome. Relapse rather than progression was also associated
with a better prognosis with a HR of 0.42 (Po0.0001; Table 3). There
was no impact on outcome from the following variables: gender,
conditioning with TBI, stem cell source (Table 3).
After univariate analysis, a Cox model multivariate analysis on
288 patients showed the impact of the following factors on
survival: CR before relapse (HR = 0.60, Po0.004). The time interval
from transplantation to relapse was also associated with
prognosis: when comparing with relapses occurring within the
ﬁrst 90 days, days 90–182, days 183–364 and ⩾ 365 days yielded
HRs of 0.62, 0.45 and 0.29 (P⩽ 0.0001), respectively.
The median time from ﬁrst SCT to relapse/progression was
182 days. Relapse before 182 days was associated with a
statistically signiﬁcant higher rate of failure (P⩽ 0.003) than late
relapse (Table 4).
We then analyzed the impact of the therapeutic strategy on the
survival of post-transplant relapsed patients: The patients treated
by ‘chemotherapy followed by a second allogenic stem cell
transplantation’, and the patients treated by ‘chemotherapy and
donor lymphocyte infusion’ had a similar outcome (HR= 0.85,
P= 0.53) with a respective 1-year survival rate of 51 and 53.3%.
Treatment with chemotherapy alone (HR = 1.43, P= 0.04), palliative
care (HR = 4.24, Po0.0001) or DLI alone (HR= 1.94, Po0.04) were
associated with a lower survival (Table 4, Figure 3). When omitting
the missing values, the statistical analysis yielded comparable
results, except for the fact that the difference between the
second SCT and chemotherapy alone became nonsigniﬁcant
(Supplementary Table S1). Additional subgroup analyses show
that, in AML patients, a second transplant and chemotherapy+DLI
yielded similar results, superior to chemotherapy or palliative care.
Conversely, patients with ALL fared better when treated either by
second transplant, chemotherapy plus DLI or chemotherapy alone
(see Supplementary File). This highlights the higher GVL effect in
AML than in ALL.
We analyzed whether there was any interaction between late
relapse and second hematopoietic SCT/DLI by including treatment
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Figure 1. Overall survival after failure of ﬁrst stem cell transplanta-
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Figure 2. Overall survival for leukemia subtype. There is a statistically
signiﬁcant difference between acute myeloid leukemia and acute
lymphoid leukemia (po0.006).
Table 3. Cox model univariate analysis
Characteristics HR 95% CI P-value
Age (years) 0.016
0–4 1
5–9 0.64 0.46 0.90 0.01
10–14 0.94 0.68 1.30 0.72
414 1.08 0.79 1.48 0.61
Gender
Female 1.24 0.98 1.57 0.07
TBI
Yes 0.86 0.68 1.09 0.21
Stem cell source 0.21
BM 1
PB 1.39 0.96 2.02 0.08
CB 1.07 0.81 1.40 0.64
Leukemia type 0.04
AML 1
B ALL 0.72 0.56 0.93 0.01
T ALL 0.81 0.54 1.21 0.30
Biphenotypic 0.48 0.19 1.18 0.11
GvHD
Yes 0.60 0.43 0.83 0.002
Complete response
Yes 0.42 0.31 0.56 o10−5
Myeloablative regimen
Yes 0.62 0.42 0.93 0.02
Abbreviations: BM=bone marrow; CB= cord blood; CI= conﬁdence
interval; HR=hazard ratio; PB=peripheral blood. The bold values indicate
the signiﬁcant difference.
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imbalance between the therapeutic groups according to the
interval between ﬁrst SCT and failure, we found no signiﬁcant
relation between the delay of post-transplant relapse and the type
of treatment received (P= 0.90). Thus, we did not ﬁnd any
statistical relationship between time to relapse and post-relapse
treatment that might have inﬂuenced the HR obtained in Cox
models.
DISCUSSION
Older strategies for post-relapse therapy mainly relied either on a
‘heavy’ approach consisting of reinduction therapy followed by
allogeneic second transplant in remission, or on light care
including outpatient leukemia chemotherapy or in several cases
only support therapies. New treatment options including DLI
emerged in the late nineties (11). This is why we aimed at
investigating whether immunotherapeutic approaches can yield a
prolonged survival without the cost and treatment burden of a
second allogeneic transplant.
In this study, at the time of analysis, 40 patients (12%) were alive
with a median follow-up of 1315 days (range 58–4182). AL relapse
after ﬁrst allogeneic SCT still has a very poor prognosis as half of
the children did not survive more than 150 days following their
relapse or progression. Early relapse was associated with a
statistically signiﬁcantly lower outcome (P⩽ 0.003) than late
relapse. When examining the patient’s related factors inﬂuencing
outcome, this delay is the most important point to consider. The
1-year survival rates after relapse/progression ranged from 12%
for the patients having relapsed in the ﬁrst 6 months, to 56% in
those who relapsed more than 1 year after transplant (Table 5).
A previous publication studied the outcome of 25 patients under
18 years with recurrent AML after an initial SCT conditioned with a
busulfan and cyclophosphamide preparative regimen.16 The
Kaplan–Meier estimates of survival at 100 days, 1 year and
10 years were 88%, 56% and 48%, respectively. In addition,
patients who received their second SCT o6 months after the ﬁrst
transplantation were at an increased risk of relapse (Po0.03).
We have then questioned whether the type of therapeutic
approach might impact on the survival. Despite evident
limitations due to the retrospective setting of our analysis, best
treatment consisted of second transplantation or the combination
of chemotherapy plus DLI, both yielded similar long-term results.
These results must be taken with caution since the chemotherapy
+DLI group is composed of only 30 patients. In a recent report of
the Berlin/Frankfurt/Muenster Study Group, 93 children with
relapsed ALL non-responsive to chemotherapy according to ALL
relapse protocols (03/1990–2006/1999)17 were investigated. They
were retrospectively assigned to three therapeutic groups. The
median survival after curative (intensive polychemotherapies,
SCT), palliative chemotherapy or supportive care were 121,
89 and 42 days, respectively (Po0.001). Time point of relapse
and treatment strategy after failure were independent predictors
of survival duration.
We are aware that the therapeutic strategy is not independent
from the time point of relapse after SCT. The earlier the relapse,
the less the doctors and families are prone to aggressive
treatments. This is highlighted in our study by the imbalance
between the therapeutic groups according to the elapsed time
Table 4. Cox model multivariate analysis including therapy strategy
and time from transplant to failure
Characteristics HR 95% CI P-value
Post-transplant CR
No 1
Yes 0.60 0.43 0.85 0.004
Treatment o10− 5
Second transplant 1
Chemotherapy and DLI 0.85 0.52 1.40 0.53
Palliative care 4.24 2.84 6.34 o10− 5
Chemotherapy alone 1.43 1.01 2.03 0.04
DLI alone 1.94 1.03 3.64 0.04
Time from transplant to failure (days) o10− 5
0–91 1 o10− 5
92–182 0.62 0.43 0.89 0.009
183–364 0.46 0.31 0.67 o10− 5
⩾ 365 0.30 0.20 0.44 o10− 5
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Figure 3. Overall survival according to therapy after post transplant
relapse/progression.

















0 to 6 months 144 11.9 81 63.1 98.9
7 to 12 months 71 40.1 242 133.5 350.5
More than
12 months
73 56.6 514 320.3 707.7
Global 288 30.2 164 127.7 200.2
Abbreviations: CI= conﬁdence interval; SCT= stem cell transplantation.
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between ﬁrst SCT and failure (Supplementary Table S2). Median
time was shorter in the chemotherapy+DLI arm (211 days) than in
the second transplant arm (308 days). The following guidelines
could be proposed regarding the best results obtained by
allogenic approaches in AML patients. For early (⩽6 months)
relapses, taking into account the performance status of the child,
the alternatives might lie between palliative/supportive care and a
mild approach combining azacytidine plus DLI, as described
successfully in adults.18 For patients relapsing in the second
semester after transplant, reinduction chemotherapy followed by
DLI would be preferred and second transplant only proposed to
those patients with persistent positive MRD. After 1 year,
chemotherapy followed by a second transplant appears as the
best strategy ensuring long-term survival hope.
In ALL patients, very early relapses would warrant innovative
approaches with bi-speciﬁc antibodies or engineered T cells, or
palliative care. For early (7–12 months) and late (412 months)
relapses, the preferred choice would be chemotherapy, either
alone or followed by DLI. The beneﬁt of a second transplant in
patients with ALL appears questionable, even when the relapse
occurs late. The high toxicity of the TBI-based conditioning usually
used in the ﬁrst transplant might contribute to explain the high
mortality after second transplant in ALL patients. In all instances, a
comprehensive information on treatment-related risks and an
intense dialog should prevail, thus allowing the parents and the
child to participate actively in the choice between several
therapeutic options.
Speciﬁc genetic predictors and MRD strongly correlate with the
treatment outcome19–22 and may guide risk-stratiﬁed therapeutic
decisions. The development of highly sensitive MRD techniques
standardized for all patients, genetic proﬁling and identiﬁcation of
other predicting factors are required for better-individualized
treatments. Emerging therapies like bi-speciﬁc antibodies23,24
and CAR T cells25,26 will profoundly modify the landscape of
resistant ALLs, but these targeted therapies are still lacking for
childhood AML.
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